Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
72 Hammersmith Road
LondonW14 8TH
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,462.60 | 40.90 | 0.49% |
| CAC 40 | 7,733.11 | 38.67 | 0.50% |
| DAX 40 | 23,486.09 | 133.40 | 0.57% |
| Dow JONES (US) | 41,368.45 | 254.48 | 0.62% |
| FTSE 100 | 8,568.60 | 36.99 | 0.43% |
| HKSE | 22,867.74 | 91.82 | 0.40% |
| NASDAQ | 17,928.14 | 189.98 | 1.07% |
| Nikkei 225 | 37,503.33 | 574.70 | 1.56% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,663.94 | 32.66 | 0.58% |
| S&P/ASX 200 | 8,231.20 | 39.50 | 0.48% |
| SSE Composite Index | 3,342.00 | 10.00 | -0.30% |